



## 4<sup>TH</sup> LATIN AMERICAN CONFERENCE ON LUNG CANCER

**BUENOS AIRES, ARGENTINA**

### **Vera Hirsh, M.D., F.R.C.P.(C)**

Dr. Hirsh received her medical degree from Charles University in Prague, Czechoslovakia. She did a rotating internship and a two-year residency in Internal Medicine at Huntington Memorial Hospital – University of Southern California, U.S.A. She then completed her residency in Hematology at the Royal Victoria Hospital – McGill University, Montreal, Canada. Her current practice includes both Hematology and Oncology. She is Chief of the Hematology-Oncology Service at Santa Cabrini Hospital in Montreal. She is also Associate Physician, Oncology Service, at the Royal Victoria and Montreal General hospitals. She is an Associate Professor of Oncology at McGill University. She is chairing the Lung Cancer Committee of the McGill Department of Oncology since 1994. She has also chaired the Quebec Lung Cancer Committee to establish the guidelines for treatment of lung cancer. She chaired five consecutive chemotherapy Phase I/II trials in lung cancer through the Quebec Pulmonary Unit and is chairing ongoing Quebec chemotherapy trials. She is a member of the Medical Oncology and Lung Cancer Core Committees of RTOG and of Data Safety Monitoring Board (DSMB) for all phase I and II trials. She is a reviewer of many journals including Lung Cancer, Cancer, Clinical Lung Cancer, Annals of Oncology, etc. She is a member of global and national advisory boards for pharmaceutical companies. She was a chair of NCIC BR-14 Phase III trial comparing Platinum regimens with Gemcitabine/Vinorelbine in NSCLC Stage IIIB and IV. She was a member of Steering Committees of international trials, i.e. AZ INTEREST trial, Roche CERA trial, AVAIL trial (Avastin), Pfizer TLR-9 trial, Zephyr trial, and is presently on Steering Committee of BIBW 2992 trial in lung cancer. Dr. Hirsh has authored numerous articles, book chapters and abstracts.